UK-based charitable organisation Mast Cell Action is partnering with compounding pharmacy Roseway Labs in recognition of Mast Cell Activation Syndrome (MCAS) Awareness Month.
The formal partnership follows a year of collaboration between the two organisations and reflects a shared focus on supporting individuals living with mast cell disorders, including MCAS. The agreement aims to strengthen collaboration, expand joint activity, and support awareness and understanding of mast cell conditions such as MCAS, Hereditary Alpha Tryptasaemia and mastocytosis among both prescribers and patients through education, awareness initiatives and clinical support.
Roseway Labs CEO and co-founder Elizabeth Philp commented, “Many patients with MCAS experience sensitivities to standard medicines and have unique clinical needs that require a more tailored treatment approach. Our pharmacy compounds medicines free from common allergens and irritants that may trigger reactions, supporting clinicians with bespoke solutions for underserved patient groups.”